WallStSmart
PHXM

PHAXIAM Therapeutics S.A.

NASDAQ: PHXM · HEALTHCARE · BIOTECHNOLOGY

$3.10
+0.00% today

Updated 2026-11-16

Market cap
$28.90M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-39.05
Dividend yield
—
52W range
$0 – $0
Volume
—

PHAXIAM Therapeutics S.A. (PHXM) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20102011201220132014201520162017201820192020202120222023
Total assets$6.56M$4.94M$10.14M$17.95M$40.61M$53.00M$44.97M$195.26M$167.84M$118.55M$80.40M$66.77M$45.81M$51.31M
Cash & equivalents$100000.00$500000.00$7.88M$15.11M$36.99M$45.63M$37.65M$185.53M$134.37M$73.17M$44.45M$33.70M$38.79M$10.47M
Current assets$5.10M$3.66M$9.14M$17.04M$39.53M$51.93M$42.53M$191.57M$149.91M$81.58M$49.63M$40.05M$42.63M$16.22M
Total liabilities$2.09M$6.21M$14.17M$4.36M$4.78M$5.87M$9.33M$13.84M$22.24M$32.99M$53.86M$43.92M$22.32M$25.70M
Current liabilities$1.70M$1.68M$7.48M$3.51M$4.26M$5.62M$6.35M$11.61M$20.65M$19.88M$29.35M$20.00M$11.68M$15.26M
Long-term debt—————————$1.32M$14.38M$15.23M$7.55M—
Shareholder equity$3.99M$-1.91M$-4.03M$13.59M$35.82M$47.13M$35.64M$181.42M$145.60M$85.56M$26.54M$22.84M$23.49M$25.61M
Retained earnings$-4.84M$-5.91M$-2.17M$-8.14M$-8.86M$-15.01M$-21.91M$-33.53M$-38.22M$-62.66M$-73.30M$-53.80M$-228000.00—
Accounts receivable$1.70M$1.19M$998675.00$1.69M$2.12M$5.91M$4.40M$4.54M$9.68M$3.62M$4.33M$4.71M$2.58M$4.86M
Inventory$91150.00$98060.00$115983.00$138238.00$198356.00$166000.00$145000.00$176000.00$1.40M$358000.00$-8000.00$-7000.00$1.27M—
Goodwill—————————————$9.62M

Frequently asked questions

What is PHAXIAM Therapeutics S.A.'s revenue?

PHAXIAM Therapeutics S.A.'s trailing twelve-month revenue is $5.97M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How much free cash flow does PHXM generate?

PHXM produced $-24.58M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PHXM's balance sheet healthy?

PHXM holds $10.47M in cash and equivalents against — in long-term debt, on $25.61M of shareholder equity. That debt is best read against the cash flow the business throws off each year.